Phase I/II Study of Increasing Doses of Lutetium-177 Labeled Chimeric Monoclonal Antibody cG250 (177^Lu-DOTA-cG250) in Patients With Advanced Renal Cancer

Trial Profile

Phase I/II Study of Increasing Doses of Lutetium-177 Labeled Chimeric Monoclonal Antibody cG250 (177^Lu-DOTA-cG250) in Patients With Advanced Renal Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Monoclonal antibody G250 Lu-177 (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 May 2011 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 09 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top